A Phase 3 Randomized Double-Blind Clinical Study of Pembrolizumab +Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum
Brief description of study
If you have been diagnosed with advanced bladder cancer and you have been previously treated with platinum-containing chemotherapy, you may qualify for this Phase 3 study. The main goal of this study is to see if it is safe, effective and tolerable to give the study drugs, pembrolizumab and epacadostat to patients with advanced bladder cancer.
Clinical Study Identifier: s17-00840
ClinicalTrials.gov Identifier: NCTs17-00840
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
